Ghent University Academic Bibliography

Advanced

Gonadal pathology and tumor risk in relation to clinical characteristics in patients with 45,X/46,XY mosaicism

Martine Cools UGent, J Pleskacova, H Stoop, Piet Hoebeke UGent, Erik Van Laecke UGent, SLS Drop, J Lebl, JW Oosterhuis, LHJ Looijenga and KP Wolffenbuttel (2011) JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 96(7). p.E1171-E1180
abstract
Context: Gonadectomy is avoided whenever possible in boys with 45,X/46,XY. However, no clinical markers are currently available to guide clinicians in predicting gonadal tumor risk or hormone production. Objective: The objective of the study was to test the hypothesis that gonadal histology and risk for development of a malignant germ cell tumor are reflected by the clinical presentation of a 45, X/46, XY individual. Design: The design of the study was the correlation of clinical data [external masculinization score (EMS), pubertal outcome] with pathology data (gonadal phenotype, tumor risk). Setting: This was a multicenter study involving two multidisciplinary disorder of sex development teams. Patients: Patients included genetically proven 45, X/46, XY (and variants) cases, of whom at least one gonadal biopsy or gonadectomy specimen was available, together with clinical details. Interventions: Patients (n = 48) were divided into three groups, based on the EMS. Gonadal histology and tumor risk were assessed on paraffin-embedded samples (n = 87) by morphology and immunohistochemistry on the basis of established criteria. Main Outcome Measures: Gonadal differentiation and tumor risk in the three clinical groups were measured. Clinical outcome in patients with at least one preserved gonad was also measured. Results: Tumor risk in the three groups was significantly related to the gonadal differentiation pattern (P < 0.001). In boys, hormone production was sufficient and was not predicted by the EMS. Conclusions: The EMS reflects gonadal differentiation and tumor risk in patients with 45, X/46, XY. In boys, testosterone production is often sufficient, but strict follow-up is warranted because of malignancy risk, which appears inversely related to EMS. In girls, tumor risk is limited but gonads are not functional, making gonadectomy the most reasonable option.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
SEX DEVELOPMENT DSD, GERM-CELL TUMORS, CARCINOMA IN-SITU, DYSGENETIC GONADS, MATURATION DELAY, CANDIDATE GENE, GONADOBLASTOMA, DIFFERENTIATION, EXPRESSION, DISORDERS
journal title
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
J. Clin. Endocrinol. Metab.
volume
96
issue
7
pages
E1171 - E1180
Web of Science type
Article
Web of Science id
000292454500019
JCR category
ENDOCRINOLOGY & METABOLISM
JCR impact factor
5.967 (2011)
JCR rank
15/121 (2011)
JCR quartile
1 (2011)
ISSN
0021-972X
DOI
10.1210/jc.2011-0232
language
English
UGent publication?
yes
classification
A1
additional info
article on behalf of the Mosaicism Collaborative Group
copyright statement
I have transferred the copyright for this publication to the publisher
id
1247047
handle
http://hdl.handle.net/1854/LU-1247047
date created
2011-05-30 12:56:22
date last changed
2016-12-19 15:42:50
@article{1247047,
  abstract     = {Context: Gonadectomy is avoided whenever possible in boys with 45,X/46,XY. However, no clinical markers are currently available to guide clinicians in predicting gonadal tumor risk or hormone production. 
Objective: The objective of the study was to test the hypothesis that gonadal histology and risk for development of a malignant germ cell tumor are reflected by the clinical presentation of a 45, X/46, XY individual. 
Design: The design of the study was the correlation of clinical data [external masculinization score (EMS), pubertal outcome] with pathology data (gonadal phenotype, tumor risk). 
Setting: This was a multicenter study involving two multidisciplinary disorder of sex development teams. 
Patients: Patients included genetically proven 45, X/46, XY (and variants) cases, of whom at least one gonadal biopsy or gonadectomy specimen was available, together with clinical details. 
Interventions: Patients (n = 48) were divided into three groups, based on the EMS. Gonadal histology and tumor risk were assessed on paraffin-embedded samples (n = 87) by morphology and immunohistochemistry on the basis of established criteria. 
Main Outcome Measures: Gonadal differentiation and tumor risk in the three clinical groups were measured. Clinical outcome in patients with at least one preserved gonad was also measured. 
Results: Tumor risk in the three groups was significantly related to the gonadal differentiation pattern (P {\textlangle} 0.001). In boys, hormone production was sufficient and was not predicted by the EMS. 
Conclusions: The EMS reflects gonadal differentiation and tumor risk in patients with 45, X/46, XY. In boys, testosterone production is often sufficient, but strict follow-up is warranted because of malignancy risk, which appears inversely related to EMS. In girls, tumor risk is limited but gonads are not functional, making gonadectomy the most reasonable option.},
  author       = {Cools, Martine and Pleskacova, J and Stoop, H and Hoebeke, Piet and Van Laecke, Erik and Drop, SLS and Lebl, J and Oosterhuis, JW and Looijenga, LHJ and Wolffenbuttel, KP},
  issn         = {0021-972X},
  journal      = {JOURNAL OF CLINICAL ENDOCRINOLOGY \& METABOLISM},
  keyword      = {SEX DEVELOPMENT DSD,GERM-CELL TUMORS,CARCINOMA IN-SITU,DYSGENETIC GONADS,MATURATION DELAY,CANDIDATE GENE,GONADOBLASTOMA,DIFFERENTIATION,EXPRESSION,DISORDERS},
  language     = {eng},
  number       = {7},
  pages        = {E1171--E1180},
  title        = {Gonadal pathology and tumor risk in relation to clinical characteristics in patients with 45,X/46,XY mosaicism},
  url          = {http://dx.doi.org/10.1210/jc.2011-0232},
  volume       = {96},
  year         = {2011},
}

Chicago
Cools, Martine, J Pleskacova, H Stoop, Piet Hoebeke, Erik Van Laecke, SLS Drop, J Lebl, JW Oosterhuis, LHJ Looijenga, and KP Wolffenbuttel. 2011. “Gonadal Pathology and Tumor Risk in Relation to Clinical Characteristics in Patients with 45,X/46,XY Mosaicism.” Journal of Clinical Endocrinology & Metabolism 96 (7): E1171–E1180.
APA
Cools, Martine, Pleskacova, J., Stoop, H., Hoebeke, P., Van Laecke, E., Drop, S., Lebl, J., et al. (2011). Gonadal pathology and tumor risk in relation to clinical characteristics in patients with 45,X/46,XY mosaicism. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 96(7), E1171–E1180.
Vancouver
1.
Cools M, Pleskacova J, Stoop H, Hoebeke P, Van Laecke E, Drop S, et al. Gonadal pathology and tumor risk in relation to clinical characteristics in patients with 45,X/46,XY mosaicism. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2011;96(7):E1171–E1180.
MLA
Cools, Martine, J Pleskacova, H Stoop, et al. “Gonadal Pathology and Tumor Risk in Relation to Clinical Characteristics in Patients with 45,X/46,XY Mosaicism.” JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM 96.7 (2011): E1171–E1180. Print.